Key Takeaways
- KOMO Biosciences has granted Syngenta a Research Evaluation License to assess its proprietary KOMbine™ platform for precision genome modification.
- The collaboration focuses on evaluating non-viral, integrase-based technology for the controlled introduction of genetic programs into maize (Zea mays).
- The KOMbine™ platform aims to overcome limitations in current genetic engineering by avoiding viral delivery and nuclease-induced DNA breaks.
- Syngenta will utilize the technology to explore advanced crop trait development, targeting improvements in stress tolerance and yield stability.
- KOMO Biosciences designed its platform to support the coordinated expression of multiple genes with long-term stability across generations.
KOMO Biosciences Licenses KOMbine™ Platform to Syngenta
KOMO Biosciences, a developer of non-viral targeted insertion technologies, has announced a strategic agreement with Syngenta. Under the terms of the Research Evaluation License, Syngenta, a global leader in agricultural innovation, will assess the capabilities of the KOMO Biosciences KOMbine™ platform. The evaluation is specifically focused on precision genome engineering within maize.
The research agreement allows Syngenta to test integrase-based genome engineering for the predictable introduction of genetic programs. This early-stage study is intended to determine how precise genomic integration can facilitate the development of advanced agricultural traits.
Addressing Engineering Constraints
A primary objective of the KOMO Biosciences platform is to solve common hurdles in genetic engineering, such as the difficulty of introducing large or complex genetic payloads into specific genomic locations. Unlike traditional methods, this technology does not rely on viral delivery systems or the induction of DNA breaks via nucleases.
